ARCHIVES

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

Capitol Hill: Senate bill would allow sale of therapies for catastrophic illness after phase I trials.

December 2, 2005

NCI Workshop Summary “Incomplete,” Kopans Writes In Letter

April 16, 1993

Research Integrity: Collins’ Student Falsified Data, ORI Finds

August 22, 1997

AACR Says 5 Percent Of Meeting Registrants Couldn’t Attend Due To Volcanic Ash In Europe

April 30, 2010

NIH To Give 3 Percent Increase to Grants

March 20, 2009

Coordination, Funding Lacking In National Cancer Program: Report

October 7, 1994